Spinogenix has announced the recevial of a grant award by the National Institute of Health (NIH).  The grant award will fund research and development of a novel family of compounds to help restore the brain connections and functions lost in Alzheimer’s disease (AD) and related neurodegenerative disorders.   AD is a degenerative brain disease and the most common cause of dementia – accounting for an estimated 60 to 80 percent of dementia cases. The Alzheimer’s Association 2018 Repor...